Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prescription Influencer Shifts In India: Is Pharma Geared Up?

Executive Summary

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

You may also be interested in...



Boehringer India Chief On Putting Pedal To Metal For Digital Engagements

COVID-19 and the related lockdown has sharply curtailed pharma’s face-to-face interactions with healthcare professionals. Boehringer Ingelheim India managing director Sharad Tyagi shares insights on the “extraordinary surge” in the usage of digital platforms during these challenging times. The German multinational has been able to connect with over 30,000 HCPs across the country via digital channels.

Coronavirus Actions: How Pharma In India Is Handling Safety, Business Continuity

Scrip contacted a cross section of pharma firms in India to get a sense of how they are handling the extraordinary work-operations-employee well-being situation amid the coronavirus outbreak. Work from home mandates, deploying digital tools wherever possible, cut-back in field activities and daily temperature checks at sites are some of the initiatives set in motion.

Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece

As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel